SG11202000347UA - A composition for treating and/or preventing hepatitis b virus infection and the use thereof - Google Patents
A composition for treating and/or preventing hepatitis b virus infection and the use thereofInfo
- Publication number
- SG11202000347UA SG11202000347UA SG11202000347UA SG11202000347UA SG11202000347UA SG 11202000347U A SG11202000347U A SG 11202000347UA SG 11202000347U A SG11202000347U A SG 11202000347UA SG 11202000347U A SG11202000347U A SG 11202000347UA SG 11202000347U A SG11202000347U A SG 11202000347UA
- Authority
- SG
- Singapore
- Prior art keywords
- treating
- composition
- virus infection
- preventing hepatitis
- hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201706540X | 2017-08-10 | ||
| PCT/SG2018/050391 WO2019032046A1 (en) | 2017-08-10 | 2018-08-01 | A composition for treating and/or preventing hepatitis b virus infection and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000347UA true SG11202000347UA (en) | 2020-02-27 |
Family
ID=63524350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000347UA SG11202000347UA (en) | 2017-08-10 | 2018-08-01 | A composition for treating and/or preventing hepatitis b virus infection and the use thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11135286B2 (en) |
| EP (1) | EP3664840A1 (en) |
| KR (1) | KR20200047524A (en) |
| CN (1) | CN110944662A (en) |
| AU (1) | AU2018313636A1 (en) |
| BR (1) | BR112020002627A2 (en) |
| CA (1) | CA3070935A1 (en) |
| CU (1) | CU24699B1 (en) |
| MX (1) | MX2020001226A (en) |
| MY (1) | MY202256A (en) |
| PH (1) | PH12020500176A1 (en) |
| RU (1) | RU2020108205A (en) |
| SG (1) | SG11202000347UA (en) |
| WO (1) | WO2019032046A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU20220068A7 (en) * | 2020-05-29 | 2023-06-13 | Beijing Yisheng Biotechnology Co Ltd | IMMUNE COMPOSITION CONTAINING POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID, AN ANTIBIOTIC OR A POLYAMINE COMPOUND, AND A POSITIVE ION |
| CN111529516B (en) * | 2020-06-04 | 2022-03-15 | 山东大学 | Application of spermidine in preparation of anti-hepatitis B virus drugs |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU23031A1 (en) * | 2002-01-24 | 2005-02-23 | Ct Ingenieria Genetica Biotech | SURFACE ANTIGEN OF THE HEPATITIS B VIRUS AS A MUCOSOPT IMMUNOPOTENTIATOR, RESULTS FORMULATIONS |
| MX2007015639A (en) * | 2005-06-08 | 2008-02-15 | Newbiomed Pika Pte Ltd | Polyinosinic acid-polycytidylic acid-based adjuvant. |
| CN101501055B (en) * | 2005-06-23 | 2016-05-11 | 贝勒医学院 | The adjusting of negativity immune-regulating factor and immunotherapy application |
| US20070166800A1 (en) | 2006-01-13 | 2007-07-19 | Haixiang Lin | Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant |
| US20090136538A1 (en) | 2006-05-22 | 2009-05-28 | Jan Jezek | Stable vaccine formulation |
| HUE027823T2 (en) * | 2008-12-09 | 2016-11-28 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
| WO2014078420A1 (en) | 2012-11-13 | 2014-05-22 | Allan Wu | Methods and systems for processing exosomes |
| SG11201701520TA (en) * | 2014-09-16 | 2017-04-27 | Gilead Sciences Inc | Solid forms of a toll-like receptor modulator |
| EP3507276B1 (en) * | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018078053A1 (en) * | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| US11324820B2 (en) * | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
-
2018
- 2018-08-01 CA CA3070935A patent/CA3070935A1/en active Pending
- 2018-08-01 MX MX2020001226A patent/MX2020001226A/en unknown
- 2018-08-01 MY MYPI2020000591A patent/MY202256A/en unknown
- 2018-08-01 EP EP18766062.6A patent/EP3664840A1/en active Pending
- 2018-08-01 SG SG11202000347UA patent/SG11202000347UA/en unknown
- 2018-08-01 BR BR112020002627-1A patent/BR112020002627A2/en unknown
- 2018-08-01 US US16/630,972 patent/US11135286B2/en active Active
- 2018-08-01 CU CU2020000009A patent/CU24699B1/en unknown
- 2018-08-01 WO PCT/SG2018/050391 patent/WO2019032046A1/en unknown
- 2018-08-01 RU RU2020108205A patent/RU2020108205A/en unknown
- 2018-08-01 CN CN201880048806.4A patent/CN110944662A/en active Pending
- 2018-08-01 KR KR1020207003267A patent/KR20200047524A/en not_active Application Discontinuation
- 2018-08-01 AU AU2018313636A patent/AU2018313636A1/en active Pending
-
2020
- 2020-01-24 PH PH12020500176A patent/PH12020500176A1/en unknown
-
2021
- 2021-08-23 US US17/408,811 patent/US11690909B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20220211840A1 (en) | 2022-07-07 |
| MY202256A (en) | 2024-04-19 |
| US11135286B2 (en) | 2021-10-05 |
| WO2019032046A1 (en) | 2019-02-14 |
| KR20200047524A (en) | 2020-05-07 |
| MX2020001226A (en) | 2020-07-20 |
| PH12020500176A1 (en) | 2020-09-14 |
| US11690909B2 (en) | 2023-07-04 |
| CA3070935A1 (en) | 2019-02-14 |
| RU2020108205A3 (en) | 2022-01-31 |
| CU20200009A7 (en) | 2020-11-30 |
| BR112020002627A2 (en) | 2020-07-28 |
| US20200222529A1 (en) | 2020-07-16 |
| CN110944662A (en) | 2020-03-31 |
| RU2020108205A (en) | 2021-09-10 |
| CU24699B1 (en) | 2024-03-05 |
| EP3664840A1 (en) | 2020-06-17 |
| AU2018313636A1 (en) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1251219A1 (en) | Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection | |
| IL257384A (en) | Rnai-containing compositions and use of same for treating hepatitis b virus infection | |
| IL263558A (en) | Papd5 and papd7 inhibitors for treating a hepatitis b infection | |
| IL274298A (en) | Amino-thaizole substituted indole-z-carboxamides and compositions comprising same for use against the hepatitis b virus (hbv) | |
| HK1223931A1 (en) | Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection | |
| MA45863A (en) | ARNI AGENT AGAINST HEPATITIS B INFECTION | |
| EP3325097A4 (en) | Compositions and agents against hepatitis b virus and uses thereof | |
| EP3653630A4 (en) | Endocyclic thiamidinoamide-arylamide compound and use thereof for treating hepatitis b | |
| PH12016501379A1 (en) | Azepane derivatives and methods of treating hepatitis b infections | |
| WO2016109684A3 (en) | Derivatives and methods of treating hepatitis b infections | |
| IL282881A (en) | Methods for treating hepatitis b infection | |
| SG11202000896VA (en) | Bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders | |
| SG11202000347UA (en) | A composition for treating and/or preventing hepatitis b virus infection and the use thereof | |
| EP3556402A4 (en) | Pharmaceutical composition for preventing or treating hepatitis b | |
| PL3463469T3 (en) | Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans | |
| ZA202104244B (en) | Recombinant viruses and the uses thereof | |
| IL277128A (en) | Hepatitis b vaccines and uses of the same | |
| IL266526A (en) | Recombinant virus, composition comprising the same, and uses thereof | |
| IL279078A (en) | Combination therapy for treating hepatitis b virus infection | |
| ZA202104076B (en) | Hepatitis b virus vaccine and uses thereof | |
| GB201808500D0 (en) | Virus and virus use | |
| SG11202101660PA (en) | Composition for preventing infection with human immunodeficiency virus | |
| EP3894402C0 (en) | N-containing chromen-4-one derivatives for the treatment and prophylaxis of hepatitis b virus infection | |
| GB201813175D0 (en) | Virus use | |
| AU2017900937A0 (en) | Agents for treating or preventing viral infections and uses therefor |